Close Menu

GenomeWebinars

Wed
Jul
15
11:00 am2020
Sponsored by
LGC SeraCare Life Sciences

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Genome Webinar

Chief Scientific Officer, Foundation Medicine

Global Head of Medical Affairs,
Clinical NGS and Oncology Division, Thermo Fisher Scientific

VP Translational Science, Oncology, AstraZeneca

President & Chief Technology Officer,  Genosity

Vice President, Assay Development, Illumina

Chief Scientific Officer, LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer. However, only a minority of patients with terminal cancer have durable response with approved immuno-oncology treatments.

This webinar will feature a panel of experts in the field who will provide key insights into the current advances in cancer diagnostics and immunotherapy, as well as challenges facing the discipline.

The panelists bring a wealth of expertise and differing viewpoints in clinical laboratory practice, cancer research, translational sciences, and immuno-oncology diagnostics and therapeutics at the molecular and cellular levels important to the care and management of cancer patients and treatment outcomes. Each speaker will have an opportunity to share their perspectives on this topic, which will be moderated by Dr. Russell Garlick, Chief Scientific Officer at LGC SeraCare. The presentation will be followed by a live Q&A to allow attendees to address the experts directly.

Sponsored by

Assistant Professor of Clinical Dermatology,
University of California, Davis

Holman Research Fellow
Broad Institute

Senior Scientist,
NanoString Technologies

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response

Digital spatial profiling of immuno-oncology targets in the tumor, microenvironment, and immune compartments of archival formalin-fixed, paraffin-embedded tissue sections is coupled to downstream next-generation sequencing (NGS) readout. Our speakers will discuss how the NGS readout enables high-throughput and high-plex spatial analysis.

Our first speaker, Margaret Hoang, Senior Scientist, NanoString Technologies will provide a high level overview of the GeoMx Digital Spatial Profiler (DSP), which delivers quantitative high plex, multi-analyte spatial profiling using NGS readout.

Maija Kiuru of the University of California, Davis, will share details of a study that used NanoString’s GeoMx Cancer Transcriptome Atlas to reveal microenvironment-specific expression of a novel cell-type specific biomarker, DAMP, in response to early melanoma development. This marker may allow for more sensitive detection of melanoma via patch biopsy. 

William Hwang of the Broad Institute will then discuss how his team used GeoMx Cancer Transcriptome Atlas and Whole Transcriptome Atlas applications to profile tumor, fibroblast, and immune compartments in pancreatic ductal adenocarcinoma (PDAC) samples from twelve patients. Differential gene expression was measured in tumor and fibroblast compartments between treatment groups and by levels of immune infiltration.

Kindai Nara University Hospital,
Department of Medical Oncology

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Takayuki Takahama of Kindai Nara University Hospital will share details of the study, which enrolled 276 patients with advanced or recurrent NSCLC with known TKI-sensitizing mutations of EGFR, had documented disease progression after treatment with at least 1 first- or second-generation EGFR TKI, and were positive for the T790M mutation in plasma.

Dr. Takahama will discuss the results, which demonstrate the utility of liquid biopsy for the detection of T790M with the cobas EGFR Mutation Test v2. Plasma genotyping with this assay is informative for treatment selection in clinical practice when tumor sampling is not feasible. 

Division of Cancer Genome Research,
German Cancer Consortium and German Cancer Research Center

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

The presentation will discuss a recent study addressing the longitudinal genotyping of circulating cell-free DNA (cfDNA) from patients with ALK rearrangements by combining panel-based deep sequencing with shallow whole-genome sequencing.

The results suggest that this liquid biopsy approach might be able to improve the care of ALK-mutated NSCLC patients through early detection of resistance mutations and indications of disease progression.